Northwest Biotherapeutics reported $1.52B in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Agenus USD 35.32M 2.51M Dec/2025
AstraZeneca USD 1.55B 73K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 66.57M 20K Mar/2026
Eisai JPY 282.11M 0 Mar/2026
Infinity Pharmaceuticals USD 90K 1000 Jun/2023
Merck USD 2.47B 12.72M Dec/2025
Northwest Biotherapeutics USD 1.52B 1.52B Sep/2025
Pfizer USD 5.7B 13M Mar/2026
Plus Therapeutics USD 138.68M 7.07M Dec/2025
Roche Holding CHF 795.62M 699.54K Dec/2025